| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 06/29/2005 | CN1632118A Biology function of human nervous specific expression gene BRI3 |
| 06/29/2005 | CN1632116A Enhancement of virus-mediated DNA transfer |
| 06/29/2005 | CN1632109A Highly expressed recombinant gutted adenovirus containing human constant region whole antibody gene and its use |
| 06/29/2005 | CN1631899A Use of DLP in Pre-mRNA splicing and cell cycle control |
| 06/29/2005 | CN1631443A Targeted small interference RNA formulation for preventing and treating Hepatitis C and its preparation method |
| 06/29/2005 | CN1631442A Targeted small interference RNA formulation for treating viral Hepatitis B and its preparation |
| 06/29/2005 | CN1631441A Nucleic acid vaccine for preventing AIDS |
| 06/29/2005 | CN1631439A Curtail hemagglutinin vaccine for preventing influenza virus and its preparing method |
| 06/29/2005 | CN1208460C Application of anti-sense VEGF gene sequence |
| 06/29/2005 | CN1208087C Method and compositions useful for modulation of angiogenesis using protein kinase Raf and Ras |
| 06/28/2005 | US6911540 2′ Modified oligonucleotides |
| 06/28/2005 | US6911532 Vertebrate apoptosis gene: compositions and methods |
| 06/28/2005 | US6911320 Pituitary tumor transforming gene (PTTG), formerly pituitary tumor specific gene (PTTG) |
| 06/28/2005 | US6911220 Inactivating mature recipient t cells and introducing into a primate recipient fetal or neonatal thymic tissue from a donor of a different species; restoring thymus dependent ability for progenitors to develop into mature t cells |
| 06/28/2005 | US6911207 Cytotoxic T-cell epitopes of the papillomavirus L1-protein and use thereof in diagnostics and therapy |
| 06/28/2005 | US6911200 Administering a target cell-specific adenovirus vector, comprising an adenoviral gene essential for replication under transcriptional control of a target cell-specific transcriptional regulatory element and an anticancer agent |
| 06/28/2005 | US6911199 Targeted adenovirus vectors for delivery of heterologous genes |
| 06/28/2005 | CA2232604C Method for preserving infectious recombinant viruses, aqueous viral suspension and use as medicine |
| 06/23/2005 | WO2005057213A1 Methods and compositions for modulating mitochondrial aldehyde dehydrogenase-2 |
| 06/23/2005 | WO2005056825A1 Screening for modulators of mekk2 and mekk3 |
| 06/23/2005 | WO2005056806A2 Viral vectors controlled by a gene switch |
| 06/23/2005 | WO2005056805A1 Viral particles containing an alpha virus derived vector and method for preparing said viral particle |
| 06/23/2005 | WO2005056802A2 Materials and methods relating to cell cycle control |
| 06/23/2005 | WO2005056795A2 Hif oligonucleotide decoy molecules |
| 06/23/2005 | WO2005056793A1 Anti-apoptotically active apatamers |
| 06/23/2005 | WO2005056792A1 Long double-stranded rna for interference with lowered interferon response |
| 06/23/2005 | WO2005056762A2 Truncated cmv promoters and vectors containing same |
| 06/23/2005 | WO2005056752A2 Methods and compositions for delivering polynucleotides |
| 06/23/2005 | WO2005056749A2 Targeted gene delivery to non-phagocytic mammalian cells via bacterially derived intact minicells |
| 06/23/2005 | WO2005056594A1 Akt ACTIVITY SPECIFICALLY INHIBITING POLYPEPTIDE |
| 06/23/2005 | WO2005056590A1 Novel interaction between proteins, therapeutic agent for disuse atrophy utilizing the novel interaction, and method relating to disuse atrophy |
| 06/23/2005 | WO2005056057A1 Minimal lentiviral vector system |
| 06/23/2005 | WO2005056051A2 Hepatitis b vaccines and compositions |
| 06/23/2005 | WO2005056026A1 Compositions and methods for the treatment of lysosomal storage disorders |
| 06/23/2005 | WO2005056020A2 Nf-kb oligonucleotide decoy molecules |
| 06/23/2005 | WO2005055979A2 Ph triggerable polymeric particles or films containing a poly (beta-amino ester) |
| 06/23/2005 | WO2005055948A2 Epha2, epha4 and lmw-ptp and methods of treatment of hyperproliferative cell disorders |
| 06/23/2005 | WO2005055945A2 Mucoadhesive drug delivery devices and methods of making and using thereof |
| 06/23/2005 | WO2005055925A2 14-3-3 zeta over-expression as a poor prognosis factor, and a therapeutic target in multiple cancer types |
| 06/23/2005 | WO2005037999A9 Treatment of cancer using antibodies to lrrc15 |
| 06/23/2005 | WO2005035746A3 Medical use of tbk-1 or of inhibitors thereof |
| 06/23/2005 | WO2005034978A3 MEDICAL USE OF IKKϵ OR OF INHIBITORS THEREOF |
| 06/23/2005 | WO2005030292A3 Methods, compositions and apparatus for delivering heterologous molecules to cells |
| 06/23/2005 | WO2005023083A3 Compositions and methods for the treatment of severe acute respiratory syndrome (sars) |
| 06/23/2005 | WO2005019453A3 RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) |
| 06/23/2005 | WO2005014796A3 Methods and compositions for seamless cloning of nucleic acid molecules |
| 06/23/2005 | WO2005006958A8 Modulation of ceacam1 expression |
| 06/23/2005 | WO2005005630A3 Therapeutic use of lpi, a staphylococcal lectin pathway inhibitor in inflammatory diseases |
| 06/23/2005 | WO2004071538A3 Topical delivery of cosmetic agents |
| 06/23/2005 | WO2003102163A8 Methods of diagnosing and treating diabetes and insulin resistance |
| 06/23/2005 | US20050138676 Identification of genes involved in Alzheimer's disease using Drosophila melanogaster |
| 06/23/2005 | US20050137334 Composite nanospheres and their conjugates with biomolecules |
| 06/23/2005 | US20050137223 Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat gaucher disease |
| 06/23/2005 | US20050137160 Antisense modulation of cholesteryl ester transfer protein expression |
| 06/23/2005 | US20050137159 Methods compositions and articles of manufacture for modulating bone growth |
| 06/23/2005 | US20050137158 Methods for targeting RNA molecules |
| 06/23/2005 | US20050137154 administering human alpha interferon, double-stranded ribonucleic acid (dsRNA) and/or mixtures for the treatment of respiratory system disorders |
| 06/23/2005 | US20050137152 Reovirus for the prevention of neoplasia |
| 06/23/2005 | US20050136502 Treatment of disorders associated with elevated blood glucose or blood pressure |
| 06/23/2005 | US20050136467 Neuregulin fusion comprising epidermal growth factor domain for use in treatment and prevention of nervous system and neurodegenerative disorders |
| 06/23/2005 | US20050136430 Inhibitor nucleic acids |
| 06/23/2005 | US20050136429 SIRT1 modulation of adipogenesis and adipose function |
| 06/23/2005 | US20050136403 Molecular characterists of non-small cell lung cancer |
| 06/23/2005 | US20050136402 Cancer antigen peptide and/or major histocompatibility complex binding sites for use as tools in detection and tretment of cell proliferative disorders; immunotherapy; genetic vaccine |
| 06/23/2005 | US20050136142 Extract from the roots or stems of urticaceae for hepatitis B therapy |
| 06/23/2005 | US20050136122 Preparing and using crosslinked, water insoluble, hydrated hyaluronic acid gel particles; in vivo biostability and mechanical properties, usability; ease of injection through fine needles |
| 06/23/2005 | US20050136068 Enzymatically inactive streptococcal C5a peptidase (SCP) conjugated or linked to one or more peptides; effective in immunizing a susceptible mammal against beta-hemolytic Streptococcus |
| 06/23/2005 | US20050136042 Methods and compositions for tissue repair |
| 06/23/2005 | US20050136041 Transgenic cell comprising nucleotide sequences coding erythropoietin and/or glucagon-like peptides for use in treatment and prevention of blood and metabolic disorders; somatic and germ cell gene therapy; tissue engineering |
| 06/23/2005 | US20050136040 Peptide nucleic acid of a nucleic acid binding portion and a repressor portion of a polypeptide or peptidomimetic; drug design; gene expression inhibition |
| 06/23/2005 | US20050136036 Methods and compositions for the treatment of neurological disease |
| 06/23/2005 | US20050136035 Targeted adenovirus vectors include co-transcribed genes under transcriptional control of the same heterologous transcriptional regulatory element (TRE), wherein a second gene is under translational control of a self processing cleavage sequence or 2A sequence; cell or tissue-targeted therapy; e.g. tumor |
| 06/23/2005 | CA2568898A1 Viral vectors controlled by a gene switch |
| 06/23/2005 | CA2549404A1 Compositions and methods for the treatment of lysosomal storage disorders |
| 06/23/2005 | CA2549384A1 Kinase suppressor of ras inactivation for therapy of ras mediated tumorigenesis |
| 06/23/2005 | CA2548822A1 Mucoadhesive drug delivery devices and methods of making and using thereof |
| 06/23/2005 | CA2548254A1 Methods and compositions for modulating mitochondrial aldehyde dehydrogenase-2 |
| 06/23/2005 | CA2547922A1 Viral particles containing an alphavirus-derived vector and method for preparing said viral particle |
| 06/23/2005 | CA2543257A1 Methods and compositions for delivering polynucleotides |
| 06/22/2005 | EP1544617A2 Use of a Nifie 14 binding substance for the diagnosis and treatment of cancer |
| 06/22/2005 | EP1544299A1 Modified chimeric polypeptides with improved pharmacokinetic properties |
| 06/22/2005 | EP1544297A2 Medicament for treatment of Duchenne muscular dystrophy |
| 06/22/2005 | EP1543838A1 Feline infectious peritonitis vaccine |
| 06/22/2005 | EP1543324A2 Methods and compositions for grafting functional loops into a protein |
| 06/22/2005 | EP1543169A2 Method for determining sensitivity to a bacteriophage |
| 06/22/2005 | EP1543158A1 Regulated aptamer therapeutics |
| 06/22/2005 | EP1543145A2 Antifungal therapeutic targets |
| 06/22/2005 | EP1543110A2 Mesoderm and definitive endoderm cell populations |
| 06/22/2005 | EP1543109A2 Substances for preventing and treating autoimmune diseases |
| 06/22/2005 | EP1543034A2 Treatment and prophylaxis with 4-1bb-binding agents |
| 06/22/2005 | EP1543024A2 Cyclic amp phosphodiesterase 4d7 isoforms and methods of use |
| 06/22/2005 | EP1543020A2 Codon optimized synthetic plasmids |
| 06/22/2005 | EP1542731A2 Targeted adenoviral vector displaying immunoglobulin-binding domain and uses thereof |
| 06/22/2005 | EP1542713A2 Skrp, astray, string, vacm associated with metabolic control |
| 06/22/2005 | EP1542707A2 Compositions and methods for ligament growth and repair |
| 06/22/2005 | EP1542536A2 Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith |
| 06/22/2005 | EP1542532A1 Spliceosome mediated rna trans-splicing for correction of skin disorders |
| 06/22/2005 | EP1542528A1 A method of treatment and prophylaxis |
| 06/22/2005 | EP1140273B1 Device for locally delivering a drug in a body cavity |
| 06/22/2005 | EP1124849B1 Chlamydia 98kd putative outer membrane protein and corresponding dna fragments and uses thereof |